Esketamine maintenance dosing real-world data matures
Three-year real-world data on esketamine maintenance therapy in TRD characterises long-term response and discontinuation patterns.
Esketamine launched into treatment-resistant depression with weekly induction and biweekly-or-monthly maintenance. Three-year real-world data is now characterising long-term response durability, the proportion of patients who taper successfully, and the discontinuation patterns. The patient profile that benefits most from sustained maintenance is becoming distinct from the profile that achieves durable remission with acute treatment alone.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.